Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo

Gut

Volumn 67, Issue 3, 2018, Pages 542-552

  Allweiss, Lena ^a   Volz, Tassilo ^a   Giersch, Katja ^a   Kah, Janine ^a   Raffa, Giuseppina ^b   Petersen, Joerg ^c   Lohse, Ansgar W ^a,d   Beninati, Concetta ^b   Pollicino, Teresa ^b   Urban, Stephan ^d,e   Lütgehetmann, Marc ^a   Dandri, Maura ^a,d  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF MESSINA   (Italy)

^c DEPARTMENT OF CARDIOLOGY   (Germany)

^d German Center for Infection Research   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Antiviral Therapy; Basic Sciences; Chronic Hepatitis; Hepatitis B

Indexed keywords

BIOLOGICAL MARKER; CELL NUCLEUS DNA; CIRCULAR DNA; COVALENTLY CLOSED CIRCULAR DNA; NUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA; CYTOKERATIN 18; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; KRT18 PROTEIN, HUMAN; LAMIVUDINE; LIPOPEPTIDE; MYRCLUDEX-B; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIVISION; CELL GROWTH; CELL PROLIFERATION; CELL SEPARATION; CELL TRANSPLANTATION; DAUGHTER CELL; DISEASE MARKER; DNA SEQUENCE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN SITU HYBRIDIZATION; IN VIVO STUDY; LIVER CELL; MOLECULAR STABILITY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REINFECTION; VIRUS DNA CELL DNA INTERACTION; VIRUS TRANSMISSION; ANIMAL; BLOOD; CHIMERA; CHRONIC HEPATITIS B; DISEASE MODEL; GENETICS; METABOLISM; PHYSIOLOGY; PRIMARY CELL CULTURE; RECURRENT DISEASE; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; CELL DIVISION; CELL PROLIFERATION; CHIMERA; DISEASE MODELS, ANIMAL; DNA, CIRCULAR; DNA, VIRAL; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; KERATIN-18; LAMIVUDINE; LIPOPEPTIDES; MICE; PRIMARY CELL CULTURE; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD; VIRUS INTEGRATION; VIRUS REPLICATION;

EID: 85042868989     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-312162     Document Type: Article

References (53)

1. Nassal M. HBV cccDNA: Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 2015;64:1972-84.
2. Zeisel MB, Lucifora J, Mason WS, et al. Towards an HBV cure: State-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure. Gut 2015;64:1314-26.
3. Liang TJ, Block TM, McMahon BJ, et al. Present and future therapies of hepatitis B: From discovery to cure. Hepatology 2015;62:1893-908.
4. Allweiss L, Volz T, Lütgehetmann M, et al. Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration. J Hepatol 2014;60:500-7.
5. Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014;343:1221-8.
6. Belloni L, Allweiss L, Guerrieri F, et al. IFN-inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012;122:529-37.
7. Levrero M, Pollicino T, Petersen J, et al. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009;51:581-92.
8. Nassal M. Hepatitis B viruses: Reverse transcription a different way. Virus Res 2008;134:235-49.
9. Fallot G, Neuveut C, Buendia MA. Diverse roles of hepatitis B virus in liver cancer. Curr Opin Virol 2012;2:467-73.
10. Mason WS, Liu C, Aldrich CE, et al. Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection. J Virol 2010;84:8308-15.
11. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-8.
12. Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut 2012;61(Suppl 1):i6-17.
13. Liaw YF. Impact of therapy on the outcome of chronic hepatitis B. Liver Int 2013;33 (Suppl 1):111-15.
14. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675-84.
15. Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Invest 1997;99:1472-7.
16. Guidotti LG, Rochford R, Chung J, et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284:825-9.
17. Mason WS, Litwin S, Xu C, et al. Hepatocyte turnover in transient and chronic hepadnavirus infections. J Viral Hepat 2007;14(Suppl 1):22-8.
18. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: Towards restoration of immune control of viral infection. Gut 2012;61:1754-64.
19. Addison WR, Walters KA, Wong WW, et al. Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol 2002;76:6356-63.
20. Lutgehetmann M, Volz T, Köpke A, et al. In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology 2010;52:16-24.
21. Köck J, Rösler C, Zhang JJ, et al. Generation of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner. PLoS Pathog 2010;6:e1001082.
22. Hantz O, Parent R, Durantel D, et al. Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells. J Gen Virol 2009;90(Pt 1):127-35.
23. Volz T, Allweiss L, Ben MBarek M, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2013;58:861-7.
24. Giersch K, Allweiss L, Volz T, et al. Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection. J Hepatol 2015;63:346-53.
25. Joseph B, Malhi H, Bhargava KK, et al. Kupffer cells participate in early clearance of syngeneic hepatocytes transplanted in the rat liver. Gastroenterology 2002;123:1677-85.
26. Dandri M, Burda MR, Török E, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 2001;33:981-8.
27. Xia Y, Stadler D, Lucifora J, et al. Interferon-A nd tumor necrosis factor-produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology 2016;150:194-205.
28. Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003;77:68-76.
29. Hösel M, Quasdorff M, Wiegmann K, et al. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 2009;50:1773-82.
30. Palumbo GA, Scisciani C, Pediconi N, et al. IL6 Inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA minichromosome. PLoS ONE 2015;10:e0142599.
31. Liang G, Liu G, Kitamura K, et al. TGF-suppression of HBV RNA through AID-dependent recruitment of an RNA exosome complex. PLoS Pathog 2015;11: E1004780.
32. Petersen J, Dandri M, Mier W, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008;26:335-41.
33. Schulze A, Schieck A, Ni Y, et al. Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J Virol 2010;84:1989-2000.
34. Saitta C, Tripodi G, Barbera A, et al. Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma. Liver Int 2015;35:2311-17.
35. Minami M, Poussin K, Bréchot C, et al. A novel PCR technique using Alu-specific primers to identify unknown flanking sequences from the human genome. Genomics 1995;29:403-8.
36. Murakami Y, Saigo K, Takashima H, et al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 2005;54:1162-8.
37. Moraleda G, Saputelli J, Aldrich CE, et al. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997;71:9392-9.
38. Lechardeur D, Sohn KJ, Haardt M, et al. Metabolic instability of plasmid DNA in the cytosol: A potential barrier to gene transfer. Gene Ther 1999;6:482-97.
39. Wang X, Le N, Denoth-Lippuner A, et al. Asymmetric partitioning of transfected DNA during mammalian cell division. Proc Natl Acad Sci USA 2016;113:7177-82.
40. Reaiche-Miller GY, Thorpe M, Low HC, et al. Duck hepatitis B virus covalently closed circular DNA appears to survive hepatocyte mitosis in the growing liver. Virology 2013;446:357-64.
41. Lucifora J, Protzer U. Attacking hepatitis B virus cccDNA-the holy grail to hepatitis B cure. J Hepatol 2016;64(1 Suppl):S41-8.
42. Wu BK, Li CC, Chen HJ, et al. Blocking of G1/S transition and cell death in the regenerating liver of hepatitis B virus X protein transgenic mice. Biochem Biophys Res Commun 2006;340:916-28.
43. Koh S, Bertoletti A. Circumventing failed antiviral immunity in chronic hepatitis B virus infection: Triggering virus-specific or innate-like T cell response Med Microbiol Immunol 2015;204:87-94.
44. Hai H, Tamori A, Kawada N. Role of hepatitis B virus DNA integration in human hepatocarcinogenesis. World J Gastroenterol 2014;20:6236-43.
45. Summers J, Jilbert AR, Yang W, et al. Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci USA 2003;100:11652-9.
46. Dandri M, Bürda MR, Burkle A, et al. Increase in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly(ADP-ribosyl)ation. Hepatology 2002;35:217-23.
47. Qasim W, Brunetto M, Gehring AJ, et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 2015;62:486-91.
48. Mason WS, Jilbert AR, Summers J. Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. Proc Natl Acad Sci USA 2005;102:1139-44.
49. Mason WS, Low HC, Xu C, et al. Detection of clonally expanded hepatocytes in chimpanzees with chronic hepatitis B virus infection. J Virol 2009;83:8396-408.
50. Guo JT, Zhou H, Liu C, et al. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections. J Virol 2000;74:1495-505.
51. Hadziyannis SJ, Sevastianos V, Rapti I, et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012;143:629-36.e1.
52. Chang ML, Liaw YF, Hadziyannis SJ. Systematic review: Cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2015;42:243-57.
53. Höner Zu Siederdissen C, Rinker F, Maasoumy B, et al. Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J Infect Dis 2016;214:1492-7.